Navigation Links
Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers
Date:3/5/2009

anyladenine) in improving the clinical signs and symptoms of rosacea. Subjects were evaluated through physician assessments of inflammatory lesion count (papules and pustules), severity of erythema (redness) and telangiectasia (spider veins) and overall clinical improvement, as well as through patient assessments of signs and symptoms of rosacea and skin tolerance.

After 48 weeks, there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. The investigators saw continual, statistically significant mean improvement with Pyratine XR(TM) treatment, including a 90% improvement in lesions, 45% improvement in erythema and a 28% improvement in telangiectasia. The product was well tolerated, and in an earlier assessment of 24 patients, there was a 41% mean improvement in skin dryness as early as week four, with results continuing to improve over the 48-week period. Pyratine XR(TM) produced a significant improvement in skin barrier function at weeks 4 through 48 as measured by a decrease in water loss from the skin.

According to the National Rosacea Society, more than 14 million Americans have rosacea, yet only a small fraction are being treated. The chronic skin disease can affect adults and children of any skin type. While the cause is unknown and there is no cure, scientific advancements are now offering rosacea sufferers hope and a way to control the signs and symptoms of this potentially life-disruptive disorder.

For more information, please visit Senetek at Booth #5736 or online at www.PyratineXR.com.

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with b
'/>"/>

SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
2. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
3. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
4. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
5. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
6. Video: Keppra XR(TM) Approved in the U.S.
7. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
8. Novozymes Launches Enzyme to Reduce Acrylamide in Food
9. Enova Medical Launches Exos Corporation
10. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... DIEGO, Jan . 8 Arena Pharmaceuticals, Inc. (Nasdaq: ... to present at the 27th Annual J.P. Morgan Healthcare Conference ... p.m. Eastern Time) at the Westin St. Francis Hotel in ... is scheduled to provide an overview of the company, including ...
... 8 Palomar Medical Technologies, Inc. (Nasdaq: ... of light-based systems for cosmetic treatments, today announced ... the Swedish company Q-MED AB (OMX Nordic Exchange, ... based in Uppsala, Sweden. The international distribution ...
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference 3Palomar and Q-MED AB Terminate International Distribution Agreement 2Palomar and Q-MED AB Terminate International Distribution Agreement 3Palomar and Q-MED AB Terminate International Distribution Agreement 4Palomar and Q-MED AB Terminate International Distribution Agreement 5Volcano Announces Closing of Axsun Technologies Acquisition 2
(Date:10/22/2014)... Inc. (NASDAQ: AWRE ), a leading supplier of ... third quarter ended September 30, 2014. Revenue for ... of 40% compared to $4.3 million in the same quarter ... was $4.1 million compared to $1.0 million in the third ... month period was primarily due to: i) a $1.0 million ...
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... better understanding of brain injury, a way to rejuvenate ... monitor their glaucoma at home, number among this years ... What surprises me every time I walk through ... involving so many NJIT graduate and undergraduate students, said ...
... French . , A new brain-imaging study by ... ghrelin - a stomach hormone, acts on specific regions of ... and eating for pleasure. This study, published in the ... understanding and treating obesity, a condition affecting millions world-wide. ...
... The potential of no-tillage (NT) soils for increasing the soil ... Most of the previous studies about SOC accrual in NT ... depth), and not for the whole soil profile. The lack ... to conclusively ascertain the effects of NT farming on SOC ...
Cached Biology News:NJIT applauds students for studies on brain injury, glaucoma and more 2Hunger hormone: Makes food more attractive 2Finding the real potential of no-till farming for sequestering carbon 2
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 beta, CF...
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: